CEL-SCI Plunges 13.31% on Stock Offering

On July 14, 2025, CEL-SCI's stock experienced a significant drop of 13.31% in pre-market trading.

CEL-SCI recently announced a $5.7 million stock offering, selling 1.5 million shares of common stock at $3.82 per share. This offering was priced at-the-market under NYSE American rules, aiming to raise funds for the company's ongoing operations and development projects.

Genomill Health, a biotechnology company, published results from a clinical pilot study in Scientific Reports. The study demonstrated the high sensitivity of its Bridge Capture™ technology for mutation profiling in cell-free DNA from metastatic colorectal cancer patients. This technology could potentially impact the diagnostic and treatment landscape for colorectal cancer, which may indirectly affect CEL-SCI's market position and investor sentiment.